Oscar Health, Inc. (OSCR) saw its stock rise by 3.08% to close at $15.75 on February 5, 2025, despite a challenging start to the day. The stock opened at $15.02 and initially dropped to a low of $14.11 following the release of its fourth-quarter 2024 earnings, which revealed a wider-than-expected loss of $0.62 per share and revenue of $2.39 billion, both missing analyst expectations. However, the stock rebounded sharply, reaching an intraday high of $16.27, driven by positive sentiment surrounding the company's first profitable year in 2024, as reported by Oscar Health. The company achieved a full-year profit of $25.4 million, buoyed by a significant increase in enrollment in Affordable Care Act plans, which grew by 37% compared to the previous year.
Investor sentiment was further bolstered by Baird's analyst Michael Ha, who viewed the initial weakness in Oscar Health's stock as a buying opportunity, reiterating an "Outperform" rating and a $28 price target. This optimistic outlook, coupled with the company's strategic leadership changes and focus on operational expertise, helped lift the stock from its early losses. The trading volume was notably high, at 10,652,161 shares, more than double the average, indicating strong investor interest.